Advertisement
Articles
Advertisement

Current Trends in Milling Technology

Thu, 09/22/2011 - 12:08pm
Martin Hack, Vice President and General Manager, L.B. Bohle LLC, and Lester Lattig, Regional Sales Manager at L.B. Bohle

LISTED UNDER:

No pharmaceutical processing line is complete without a mill for handling both active and inactive materials for the manufacture of tablets and other products. To date, cone mills and hammer mills still play some of the largest roles in pharmaceutical processing due to their versatility.

Both cone mills and hammer mills have smaller footprints in processing environments where space is at a premium. Many of these mills are now equipped with integrated lifting columns, allowing them to adjust to fit into virtually any processing line. Further, their portability allows manufacturers to increase efficiency by moving — and sometimes dismantling — them quickly for cleaning.

Here are some of the latest trends in cone and hammer milling, including a look into how one manufacturer increased its processing efficiencies by installing three new hammer mills.

Cone Milling

Cone mills, or conical screen mills, have been used traditionally to reduce the size of pharmaceutical ingredients in a uniform manner.However, they also can be used for mixing, sieving and dispersion. They come in a variety of sizes, including tabletop laboratory devices to full-scale, high-capacity machines used for large pharmaceutical processing operations.

While the uses of cone mills vary, the trend toward using them in pharmaceuticals includes de-lumping dried materials during production; sizing wet granulated particles prior to drying; and sizing dry granulated particles after they are dried and prior to tableting.

Compared to other milling technologies, the cone mill also offers other specific advantages to pharmaceutical manufacturers. These benefits include lower noise, more uniform particle size, design flexibility and higher capacity.

The most innovative milling technology on the market today offers greater throughput and product size distribution. In addition, they are available with variable sieve (screen) and impeller options. When used with low-density materials, a sieve can increase throughput by more than 50 percent compared to mills designed with straight bars. In some cases, users have achieved unit production capacity of up to 3 tons per hour.

Achieving Dust-Free Cone Milling

It is well known that milling generates dust, which can be particularly hazardous to operators and the pharmaceutical processing environment if the dust is not contained. There are several methods available for dust containment.

Bin-to-bin milling is a fully in-line process that relies on gravity to feed ingredients through the cone mill. Technicians position a bin below the mill, and a bin placed directly above the mill releases materials into the mill. Gravity allows the material to pass directly into the bottom container after milling. This keeps the product contained from start to finish, as well as makes transferring the material easier post-milling.

Another method is vacuum transfer, which is also an in-line process. This process contains dust and also automated the process to help customers achieve higher efficiency and cost savings. Using an in-line vacuum transfer system, technicians can feed materials through the cone's chute and have them automatically pulled from the mill’s outlet. Thus, from start to finish, the process is fully enclosed.

Finally, isolator milling is recommended to contain fine powders during milling. With this method, the cone mill integrates with an isolator through a wall fixing flange. The flange and configuration of the cone mill allow for a physical division of the cone mill head by the processing area that is outside of the isolator. This configuration allows any cleaning to be carried out inside the isolator by way of glove box. This reduces the risk of dust exposure and prevents the transfer of dust to other areas of the processing line.

Hammer Milling

Hammer mills, also called turbo mills by some pharmaceutical processing manufacturers, are typically suitable for research and product development, as well as continuous or batch production. They are often employed in cases where drug developers require precision particle reduction of difficult-to-mill APIs and other substances. In addition, hammer mills can be used to reclaim broken tablets by grinding them into powder for reforming.

For example, upon inspection, some manufactured tablets may not be up to a customer’s standards for a variety of reasons: incorrect hardness, poor appearance, and overweight or underweight. In those cases, the manufacturer can choose to mill the tablets back down to their powdered form rather than take a loss on the materials. Re-milling the tablets and introducing them back into production ultimately reduces waste and increases productivity. In almost all situations where a batch of tablets does not meet specifications, manufacturers can use a hammer mill to overcome the issue.

Hammer mills are capable of operating at speeds ranging from 1,000 rpm to 6,000 rpm while producing up to 1,500 kilograms per hour. To achieve this, some mills come equipped with an automatic rotating valve that permits technicians to fill the milling chamber evenly with ingredients without overfilling. Besides preventing overfill, such automatic feeding devices can control the flow of powder into the milling chamber to increase process repeatability and reduce heat generation.

Some of the more advanced hammer mills have a dual-sided blade assembly that increases the viability of wet or dry ingredients. One side of the blade acts as a hammer to shatter dry materials, while a knife-like side can slice through wet ingredients. Users simply flip the rotor based on the ingredients they are milling. Additionally, some mill rotor assemblies can be reversed to adjust for specific product behavior while the rotation of the mill remains unchanged.

For some hammer mills, particle size is determined based on the screen size that is chosen for the mill. Modern hammer mills can reduce material size to as small as 0.2 mm to 3 mm. Once processing is complete, the mill pushes particles through the screen, which regulates the product size. The blade and screen perform in conjunction to determine the final product size.

Hammer mills that resist pressure shocks have become desirable to pharmaceutical companies as they work with higher-toxicity APIs at risk of dust explosion. Some of these mills now resist pressure shocks up to as much as 10 bar. Shock resistance at these levels helps protect processing areas by preventing dust explosions. These mills may use a single side-mounted with rotors or hammers depending on the materials being processed. The single-mounted rotors produce less heat than double side-mounted rotor mills, allowing manufacturers to process heat-sensitive materials at a lower risk of explosion.

A Case for Turbo Milling

Historically, developers of cell culture media use ball mills to reduce the particle size of initial blends. However, the ball milling process is long and tedious, relying on ceramic balls or cylinders in a tumbling vessel to crush the media into a powder.

Once a batch is milled, technicians must clean the mill, as well as the hundreds of ceramic balls inside. Cleaning is critical between batches because the cell culture media is highly susceptible to virus contagion. The cleaning process could take up to a week, rendering the machine unusable in the event that a customer requests a custom, quick batch of powder.

One manufacturer of cell culture media sought a milling solution that would give it greater flexibility and efficiency for meeting the demands of its biopharmaceutical customers. This included finding processing equipment that had a smaller footprint and had the potential to be portable. That way it could be moved out of the room for cleaning, and that room could be dedicated to other processes during downtime.

The solution also had to meet specific processing guidelines for temperature, and particle and batch size. Cell culture media requires fine particle size for proper dissolution rates. As much as 50 percent of the batch must be smaller than 100 microns in size. Additionally, the media is very susceptible to temperatures of 100 degrees Fahrenheit or higher. At these temperatures the powder begins to lose its bioactivity.

The company approached L.B. Bohle to perform milling trials at its service center. Using a turbo mill (Model BTM-150), Bohle produced acceptable product sizing at throughput rates of 375 kilograms per hour — via rotary feed valve on top of the mill — in a bin-to-bin milling setup. Bohle engineers selected a 6,000-rpm rotor speed using the impact side of the blades.

Heat was generated and measured to be about 85 degrees Fahrenheit after a small 30 kilogram run. To better control temperatures and meet the manufacturer’s specifications, Bohle designed a production mill using a cooling jacket around the mill’s chamber, in addition to injecting nitrogen gas through the shaft lip seal.

Finally, to produce particle size similar to that yielded by a ball mill, Bohle added a 1-millimeter perforated plate inside turbo mill.

Satisfied with the results, the manufacturer purchased a turbo mill, and then proceeded to invest in two more.

After installing the new mills, the company increased its processing efficiencies. In just a few hours, technicians can disassemble and thoroughly clean the Turbo Mill between batches. The only parts in contact with product are the rotor, chamber, mill screen and rotary valve components. This offered the manufacturer a major advantage, as many batches (for example, 1,000 kg lots) could be milled in one week compared to one or two with the conventional ball-milling method.

About the authors:

Martin Hack is Vice President and General Manager of L.B. Bohle LLC in Warminster, Pa.  He can be reached at martinhack@lbbohle.com

Lester Lattig is Regional Sales Manager at L.B. Bohle in Warminster, Pa. He can be reached at leslattig@lbbohle.com

References

1. Schenck LR, Plank RV. Impact milling of pharmaceutical agglomerates in the wet and dry states. International Journal of Pharmaceutics. 2008;348(1-2):18-26. 

 

 

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading